Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer, centered on the isotope lead-212. Its programs pair imaging diagnostics with therapeutic agents so tumors can be visualized and then treated with the same targeting approach. Pipeline candidates address areas such as neuroendocrine tumors and melanoma and remain in early- to mid-stage clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -18.2 | — |
| Q2 2025 | 0 | — | -21.5 | — |
| Q3 2025 | 0 | — | -26 | — |
| Q4 2025 | 0 | — | -37.5 | — |
| Q1 2026 | 0 | — | -26.2 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE American: Gran Tierra Energy Inc. (GTE), Envela Corporation (ELA), Blue Ridge Bankshares, Inc. (BRBS), M-tron Industries, Inc. (MPTI), SMJ International Holdings Inc. (SMJF), Legato Merger Corp. IV (LEGO)